Risk of hypomagnesaemia with proton pump inhibitors

Australian Prescriber

Volumn 34, Issue 3, 2011, Pages 81-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

LOOP DIURETIC AGENT; MAGNESIUM; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT;

ARTICLE; DELIRIUM; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART ARRHYTHMIA; HOMEOSTASIS; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; RISK ASSESSMENT; SEIZURE; TETANY;

EID: 79958786443     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006;355:1834-6.
2. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011;27:180-5.
3. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. Q J Med 2010;103:387-95.
4. Wu J, Carter A. Abnormal laboratory results. Magnesium: the forgotten electrolyte. Aust Prescr 2007;30:102-5.
5. United States Food and Drug Administration. FDA drug safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs. Silver Spring, MD: FDA; 2011 Mar 2. www.fda.gov/Drugs/DrugSafety/ucm245011.htm [cited 2011 May 4]